Edesa Biotech’s New CFO: A Strategic Move with Industry Veteran Peter J. Weiler
Edesa Biotech appoints Peter J. Weiler as the new Chief Financial Officer, effective May 2025, succeeding Stephen Lemieux. Weiler brings extensive experience in corporate finance and strategic development from Exzell…
Edesa Biotech Navigates Leadership Change with Strategic Vision and Steadfast Confidence
Edesa Biotech announces the appointment of Peter J. Weiler as the new Chief Financial Officer (CFO) starting May 2025, succeeding Stephen Lemieux. Peter J. Weiler brings extensive experience from roles…
The Breakthrough Alliance Driving mRNA Therapies to New Heights
The collaboration between and heralds a new era for mRNA-based therapies, promising to redefine the biopharmaceutical landscape. Wacker Biotech offers robust manufacturing capabilities with a 650-liter fermentation capacity, crucial for…
Behind the Scenes: A Key Leadership Shift at Edesa Biotech
Edesa Biotech appoints Peter J. Weiler as the new Chief Financial Officer, effective May 1, 2025, to lead financial strategy in developing therapies for immuno-inflammatory diseases. Stephen Lemieux transitions to…
Shifting Tides at Edesa Biotech: A New CFO Brings Transformative Vision
The appointment of Peter J. Weiler as CFO marks a strategic shift for Edesa Biotech, effective May 1, 2025. Weiler brings extensive experience from roles at Exzell Pharma, Biosyent Inc.,…
Leadership Shuffle at Edesa Biotech Signals Strategic Advancements
Edesa Biotech has appointed Peter J. Weiler as its new Chief Financial Officer, effective May 1, 2025. Weiler brings extensive experience from leadership roles at Exzell Pharma, Biosyent Inc., and…
The mRNA Revolution: A New Alliance Promises to Reshape Biopharma Landscape
Wacker Biotech and RNAV8 Bio's collaboration advances mRNA-based therapies, merging manufacturing and mRNA engineering expertise. Wacker Biotech brings pharmaceutical-grade pDNA and protein production capabilities with high-capacity fermentation lines. RNAV8 Bio…
Revolutionizing Medicine: The Unstoppable Alliance Changing mRNA Therapeutics Forever
Wacker Biotech and RNAV8 Bio have joined forces to revolutionize mRNA engineering, transforming treatments for genetic and common diseases. Wacker Biotech specializes in producing high-quality mRNA and formulating lipid nanoparticles…
This Groundbreaking Partnership Might Change the Game for mRNA Therapeutics
Wacker Biotech and RNAV8 Bio have formed a strategic partnership to advance mRNA therapeutics. Wacker Biotech brings its expertise in microbial fermentation, processing up to 650 liters of material, to…
The Fall of a Biotech Titan: What Happened to AmplifyBio?
AmplifyBio, a promising biotech company based in central Ohio, has closed its operations, despite its ambitious beginnings and significant investments. Founded in 2021 as a gene therapy offshoot from Battelle,…